Can-Fite BioPharma Begins Phase III in Dry Eye Syndrome

Can-Fite BioPharma Ltd …announced Tuesday that it has opened an Investigational New Drug application with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.
Earth Times